Shanghai Concord Cancer Center is one of the high-end tertiary-level three-level oncology hospitals jointly constructed, managed and operated in Beijing, Shanghai and Guangzhou under the comprehensive strategic cooperation framework of Concord Medical Group, a domestic operating platform of Concord Holdings (NYSE: CCM). With the goal of "internationalization and standardization", the Center will promote the integrated development of medical services, clinical translational medicine, and personnel training.

The Center is located in Shanghai New Hongqiao International Medical Center that is in the hinterland of Hongqiao hub and 5.3 kilometers away from Hongqiao Airport, and it is the key member of the high-end medical service cluster in the Medical Center which establishes itself in Shanghai, reaches out to the Yangtze River Delta, serves the whole China, and opens up to the outside world.

It has a construction area of about 160,000 square meters, and has planned to open 400 beds. The hospital will introduce international advanced treatment methods, medical procedures and management models, configure the world's leading tumor diagnosis and treatment equipment (including proton/heavy ion radiotherapy systems), and adopt international multidisciplinary tumor diagnosis and treatment methods and standardized whole-course management, so as to provide tumor patients with world-leading high-quality medical services featuring proton therapy.